Stephen Frye, PhD
  • Director, Center for Integrative Chemical Biology and Drug Discovery
  • Fred Eshelman Distinguished Professor
You are here: Home / Directory / Stephen Frye, PhD

Stephen Frye, PhD

Research Synopsis

The Center for Integrative Chemical Biology and Drug Discovery was created with the mission of bringing dedicated medicinal chemistry expertise to bear on biological targets of therapeutic relevance under investigation by UNC faculty. Synthetic chemists, assay development and compound profiling scientists will work in the Center and create dedicated, multidisciplinary project teams with other groups on campus in order to progress targets through the drug discovery and development process.

Stephen Frye is a professor and director of the Center for Integrative Chemical Biology and Drug Discovery at the University of North Carolina in Chapel Hill. Frye is also the lead principal investigator for the North Carolina Comprehensive Chemical Biology Center, a UNC-based, NCI designated center that engages in oncology drug discovery. His research focuses on chemical biology of chromatin regulation and drug discovery

After obtaining a BS in chemistry at North Carolina State University in 1983, Frye joined the laboratory of Professor Ernest Eliel at UNC-Chapel Hill. Frye's research at UNC focused on asymmetric synthesis and included an off-campus research fellowship in Lausanne, Switzerland, to investigate mechanisms of stereoselective organometallic reactions via NMR kinetics.

Upon completing his PhD in 1987, Frye began his professional career as a medicinal chemist at the newly initiated US research site for Glaxo, located at that time in temporary facilities in Venable Hall on the UNC campus. He subsequently led the project that resulted in Avodart, GlaxoSmithKline’s dual 5a-reductase inhibitor for treatment of benign prostatic hyperplasia. The drug is currently under investigation for the prevention of prostate cancer.

Shortly after Glaxo merged with Wellcome in 1995, Frye established a new chemistry department in the Research Triangle Park based upon kinase target class science and GSK’s kinase inhibitors. Tykerb (a dual erbB2/EGFR inhibitor approved for the treatment of metastatic breast cancer) and Pazopanib (in Phase III trials for renal carcinoma) were discovered within this department. In 1999 he began a secondment at GW’s Stevenage site in the United Kingdom leading a research unit in medicinal chemistry. Following the merger with GSK in the spring of 2000, he was selected to lead GSK’s High Throughput Chemistry Group that evolved into Discovery Medicinal Chemistry (DMC).

Over the seven years Frye led DMC, the group grew to more than 200 chemists and developed global target-class chemical science and a compound collection strategy that enhanced both the productivity and quality of GSK’s hit and lead generation across all therapeutic areas. Stephen joined the UNC School of Pharmacy in October 2007 to create the CICBDD in cooperation with the Lineberger Comprehensive Cancer Center, the School of Medicine, and the Department of Chemistry.

Document Actions